Pfizer

The CDC advisory panel backed the decision for Pfizer COVID-19 booster shots for millions of older or otherwise vulnerable Americans.

A CDC panel of advisers voted to recommend a booster shot of Pfizer’s COVID-19 vaccine to people over 65 and high risk Americans, backing a similar decision by the FDA.

The FDA authorized booster doses for Americans who are 65 and older, younger adults with underlying health conditions and those in jobs that put them at high risk for COVID-19.

Pfizer’s latest announcement that its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon marked a key step toward beginning vaccinations for youngsters. But when could that happen?

Pfizer says it’s ready to seek approval from the FDA to give its coronavirus vaccine to kids ages 5-to-11, and Chicago area doctors are hailing that news as an important step forward in finally stamping out the COVID-19 pandemic. NBC 5’s Lauren Petty has all the details and reaction.

Pfizer’s latest announcement that its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon marked a key step toward beginning vaccinations for youngsters. But when could that happen?

Here are the top headlines you need to know as you start your day on Sept. 20, 2021.

Pfizer said Monday early trial results indicate its COVID-19 vaccine is safe and effective for children ages 5 to 11

Pfizer says its COVID-19 vaccine works for children ages 5 to 11

A panel of outside experts who advise the Food and Drug Administration voted not to endorse COVID-19 booster shots of the Pfizer vaccine.

An influential federal advisory panel overwhelmingly rejected a plan Friday to give Pfizer COVID-19 booster shots to most Americans, but it endorsed the extra shots for those who are 65 or older or run a high risk of severe disease.

FDA advisers will debate Friday if there’s enough proof that a booster dose of Pfizer’s COVID-19 vaccine is safe and effective — the first step toward deciding which Americans need one and when.

Pharmaceutical giant BioNTech, which worked with Pfizer to create their mRNA coronavirus vaccine, told German news weekly Der Spiegel in an interview published Friday that it would be seeking FDA approval “over the next few weeks” for use of its vaccine in children ages 5 to 11.

With clinical trials underway to determine the safety of both the Pfizer and Moderna COVID vaccines for children under the age of 12, doctors say that data could be released next month that could pave the way for emergency use authorizations for the treatments later this year.

With clinical trials underway to determine the safety of both the Pfizer and Moderna COVID vaccines for children under the age of 12, doctors say that data could be released next month that could pave the way for emergency use authorizations for the treatments later this year. NBC 5’s Lauren Petty reports.

COVID-19 booster shots may be coming for at least some Americans but there’s still important science to be worked out about who really needs them and when. Here’s what we know about the biology behind booster decisions

Researchers in Belgium directly compared the Pfizer and Moderna COVID-19 vaccines by testing the antibodies of 2,500 health care workers after two doses of both vaccines.

Now that the FDA has given the Pfizer-BioNTech COVID-19 vaccine its stamp of full approval, doctors hope that some vaccine skeptics will finally be convinced to get the shot. As NBC News medical contributor Dr. Kavita Patel explains, the approval is also likely to lead to more vaccine mandates by employers.

The U.S. has given full approval to the COVID-19 vaccine made by Pfizer

U.S. health officials are expected to announce that they recommend booster shots of the COVID-19 vaccine eight months after receiving the second dose, according to sources.